StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)

Close on Nov 17, 2026Market cap $253.10MP/E –Yield –

Enanta Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Enanta Pharmaceuticals's price to sales ratio was 5.2× on Nov 11, 2026, against 4.6× a year earlier. Over the last 5 years it ranged from 1.6× to 15.7×, with a median of 5.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.2×+0.0
2025Dec 31, 20255.2×+3.3
2024Dec 31, 20241.8×−0.7
2023Dec 29, 20232.5×−8.7
2022Dec 30, 202211.2×−4.4
2021Dec 31, 202115.6×+8.7
2020Dec 31, 20206.9×+1.0
2019Dec 31, 20195.9×−0.7
2018Dec 31, 20186.6×−4.3
2017Dec 29, 201710.9×+3.7
2016Dec 30, 20167.2×+3.4
2015Dec 31, 20153.8×−16.0
2014Dec 31, 201419.8×+4.5
2013Dec 31, 201315.3×–

More Enanta Pharmaceuticals figures

See a number that looks wrong?